Drugs / CE-224,535
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00838058 | Jan → Mar 2009 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00782600 | Jul → Aug 2008 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00446784 | Apr → Aug 2007 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00628095 | Apr 2008 → Feb 2009 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00418782 | Jan → Aug 2007 | osteoarthritis | Pfizer | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CE 224,535 | “Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers” NCT00782600 ↗6“CE 224,535 is being developed for the treatment of rheumatoid arthritis.” NCT00446784 ↗ “Drug: CE 224,535” NCT00838058 ↗ |
| Action | Inhibit | “CE-224,535, a selective P2X(7) receptor antagonist” PMID 22382341 ↗ Mar 20121“P2X purinoceptor 7 antagonist” CHEMBL1823817 ↗ |
| Modality | Small molecule | — CHEMBL1823817 ↗ |
| Route | Oral | “500 mg po BID” NCT00628095 ↗ |
| Target | P2RX7 | “P2X purinoceptor 7 antagonist” CHEMBL1823817 ↗ |